Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Evoke Pharma ( (EVOK) ) just unveiled an announcement.
Evoke Pharma, Inc. has appointed Benjamin Smeal as a Class II director with a term expiring at the 2027 annual meeting. Smeal, a seasoned investor with a background in public equities and hedge funds, will serve on key committees, bringing valuable expertise to the board. As part of the non-employee director compensation program, he receives stock options and cash compensation, enhancing the company’s strategic direction and governance.
Learn more about EVOK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue